The HHS final rule requiring inclusion of price into all televised DTC for pharmaceuticals reimbursable under Medicare/Medicaid that have a cost greater than $35 per month was to begin this July, but manufacturers may have won a reprieve with an initial court ruling that HHS overstepped its bounds. Jeremy Schafer takes a look at the implications of this ruling, the proposed new policy, and how manufacturers can mitigate some of the risks.
AET’s Jeremy Schafer provides an overview and essential takeaways from the recent Pharmaceutical Care Management Association (PCMA) meeting, where the focus was on evolving from volume to value.
Nearly 300 cell and gene therapies are currently in development. Though not all will make it through to approval, the gene/cell therapy revolution appears to be growing unabated. What big problems might this create for payers and our current healthcare system?
Express Scripts just released its 2019 Formulary Exclusion list, marking a dramatic expansion in categories--including new disease areas thought too sensitive or rare to be managed by something as blunt as an exclusion list. In short, Express Scripts' new exclusion update is one of the most aggressive in years. Jeremy Schafer, SVP, Director, Payer Access Solutions, analyzes what the announcement means to payers.
Gene therapy has moved from the realm of science fiction to reality and is now likely to play a major role in how we will treat numerous diseases. Jeremy Schafer, SVP, Director, Payer Access Solutions, examines the promise of gene therapy and shares the results of a recent Precision for Value Rapid Pulse™ survey of payers and IDN decision makers on current and future challenges of gene therapy.
Jeremy Schafer, Senior Vice President and Director, Payer Access Solutions, examines the emergence of PBM aggregator programs, outlining the primary issues facing manufacturers and what resources are needed for proper communication to stakeholders.